Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal FilmGlobeNewsWire · Oct 14, 2026
Financial Survey: Eton Pharmaceuticals (NASDAQ:ETON) vs. Cronos Group (NASDAQ:CRON)Defense World · Oct 8, 2026
ETON Stock Surges 108% in Six Months: Here's What You Need to KnowZacks Investment Research · Oct 7, 2026
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) CapsulesGlobeNewsWire · Sep 28, 2026
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Has Consensus Price Target of $67.50 According to BrokeragesDefense World · Sep 28, 2026
Connor Clark & Lunn Investment Management Ltd. Makes New $476,000 Investment in Eton Pharmaceuticals, Inc. $ETONDefense World · Sep 2, 2026Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | $0.19 | $0.35 | Beat |
| May 14, 2026 | $0.10 | $0.05 | Miss |
| Mar 19, 2026 | $0.12 | $0.05 | Miss |
| Nov 6, 2025 | $0.16 | -$0.07 | Miss |
| Aug 7, 2025 | -$0.01 | -$0.10 | Miss |
| May 13, 2025 | $0.09 | $0.07 | Miss |